Novel NMDA Inhibitor AXS-05 Shows Promise for Alzheimer's Agitation Without Antipsychotic Risks

Axsome Therapeutics' investigational drug AXS-05 is emerging as a potential new treatment option for Alzheimer's disease-related agitation, offering hope for patients and caregivers seeking alternatives to traditional antipsychotic medications.

The drug, a novel combination of dextromethorphan and bupropion, targets the glutamate system involved in agitation through a different mechanism than currently available treatments. This unique approach could provide significant advantages in safety and tolerability.

"One of the good things about [AXS-05] is that it's not an antipsychotic, so it's not going to have the boxed warning about mortality...or knock the patient out," explains Dr. George Grossberg, Director of Geriatric Psychiatry at Saint Louis University School of Medicine.

Significant Unmet Medical Need

Agitation affects up to 70% of individuals with Alzheimer's disease, representing a substantial burden for patients and caregivers. Currently, treatment options are limited, with most physicians resorting to off-label use of antipsychotic medications that carry serious risks including somnolence, cerebrovascular events, and increased mortality.

Novel Mechanism of Action

AXS-05's effectiveness stems from its dual-component design. Dextromethorphan serves as the primary therapeutic agent, working by blocking glutamate, a neurotransmitter implicated in agitation. Bupropion, administered in low doses, plays a crucial supporting role by extending dextromethorphan's half-life, enabling practical dosing schedules.

Clinical Profile and Treatment Approach

Unlike acute interventions, AXS-05 requires approximately two weeks to demonstrate therapeutic effects. However, this gradual onset comes with notable benefits - the medication provides therapeutic relief without excessive sedation, maintaining patient alertness and quality of life.

Dr. Grossberg notes that various neurotransmitters, including norepinephrine, serotonin, and dopamine, play roles in agitation. AXS-05's targeted approach to glutamate modulation represents a novel strategy in addressing these complex neurochemical interactions.

Future Prospects

The drug is currently undergoing pivotal Phase 3 clinical trials, with additional studies in progress. If current positive trends continue, AXS-05 could join brexpiprazole as only the second FDA-approved treatment specifically indicated for Alzheimer's agitation, offering a much-needed alternative with an improved safety profile.